<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" xml:lang="EN">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">LUP</journal-id>
<journal-id journal-id-type="hwp">splup</journal-id>
<journal-id journal-id-type="nlm-ta">Lupus</journal-id>
<journal-title>Lupus</journal-title>
<issn pub-type="ppub">0961-2033</issn>
<issn pub-type="epub">1477-0962</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage UK: London, England</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/0961203312470729</article-id>
<article-id pub-id-type="publisher-id">10.1177_0961203312470729</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Papers</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Autologous haematopoietic stem cell transplantation for systemic lupus erythematosus: data from the European Group for Blood and Marrow Transplantation registry</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name><surname>Alchi</surname><given-names>B</given-names></name>
<xref ref-type="aff" rid="aff1-0961203312470729">1</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name><surname>Jayne</surname><given-names>D</given-names></name>
<xref ref-type="aff" rid="aff2-0961203312470729">2</xref>
<xref ref-type="corresp" rid="corresp1-0961203312470729"/>
</contrib>
<contrib contrib-type="author">
<name><surname>Labopin</surname><given-names>M</given-names></name>
<xref ref-type="aff" rid="aff3-0961203312470729">3</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Kotova</surname><given-names>O</given-names></name>
<xref ref-type="aff" rid="aff4-0961203312470729">4</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Sergeevicheva</surname><given-names>V</given-names></name>
<xref ref-type="aff" rid="aff5-0961203312470729">5</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Alexander</surname><given-names>T</given-names></name>
<xref ref-type="aff" rid="aff6-0961203312470729">6</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Gualandi</surname><given-names>F</given-names></name>
<xref ref-type="aff" rid="aff7-0961203312470729">7</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Gruhn</surname><given-names>B</given-names></name>
<xref ref-type="aff" rid="aff8-0961203312470729">8</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Ouyang</surname><given-names>J</given-names></name>
<xref ref-type="aff" rid="aff9-0961203312470729">9</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Rzepecki</surname><given-names>P</given-names></name>
<xref ref-type="aff" rid="aff10-0961203312470729">10</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Held</surname><given-names>G</given-names></name>
<xref ref-type="aff" rid="aff11-0961203312470729">11</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Sampol</surname><given-names>A</given-names></name>
<xref ref-type="aff" rid="aff12-0961203312470729">12</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Voswinkel</surname><given-names>J</given-names></name>
<xref ref-type="aff" rid="aff13-0961203312470729">13</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Ljungman</surname><given-names>P</given-names></name>
<xref ref-type="aff" rid="aff14-0961203312470729">14</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Fassas</surname><given-names>A</given-names></name>
<xref ref-type="aff" rid="aff15-0961203312470729">15</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Badoglio</surname><given-names>M</given-names></name>
<xref ref-type="aff" rid="aff16-0961203312470729">16</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Saccardi</surname><given-names>R</given-names></name>
<xref ref-type="aff" rid="aff17-0961203312470729">17</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Farge</surname><given-names>D</given-names></name>
<xref ref-type="aff" rid="aff18-0961203312470729">18</xref>
</contrib>
<contrib contrib-type="author">
<collab>on behalf of the EBMT Autoimmune Disease Working Party members</collab>
</contrib>
</contrib-group>
<aff id="aff1-0961203312470729"><label>1</label>Addenbrooke's Hospital, Department of Medicine, UK</aff>
<aff id="aff2-0961203312470729"><label>2</label>Addenbrooke's Hospital, Department of Rheumatology, UK</aff>
<aff id="aff3-0961203312470729"><label>3</label>ADWP-EBMT, Hôpital Saint Antoine, AP-HP, UPMC Univ Paris 06, UMR-S 938 (Paris, FR), France</aff>
<aff id="aff4-0961203312470729"><label>4</label>Novosibirsk State Medical University, Russia</aff>
<aff id="aff5-0961203312470729"><label>5</label>Institute of Clinical Immunology SB RAMS, Russia</aff>
<aff id="aff6-0961203312470729"><label>6</label>Hospital la Charité, Germany</aff>
<aff id="aff7-0961203312470729"><label>7</label>Ospedale San Martino, Italy</aff>
<aff id="aff8-0961203312470729"><label>8</label>University Hospital of Jena, Germany</aff>
<aff id="aff9-0961203312470729"><label>9</label>Drum Tower Hospital, China</aff>
<aff id="aff10-0961203312470729"><label>10</label>Military Institute of Health Services BMT Unit, Poland</aff>
<aff id="aff11-0961203312470729"><label>11</label>Saarland University Medical School, Germany</aff>
<aff id="aff12-0961203312470729"><label>12</label>Hospital Universitari Son Espases, Spain</aff>
<aff id="aff13-0961203312470729"><label>13</label>Hôpital Saint Antoine, France</aff>
<aff id="aff14-0961203312470729"><label>14</label>Karolinska University Hospital, Sweden</aff>
<aff id="aff15-0961203312470729"><label>15</label>The George Papanicolau Hospital, Greece</aff>
<aff id="aff16-0961203312470729"><label>16</label>EBMT Study Office, ADWP-EBMT, Hopital Saint-Antoine, Assistance Publique des Hôpitaux de Paris, UPMC Univ Paris 06, UMR-S 938 (Paris, FR), France</aff>
<aff id="aff17-0961203312470729"><label>17</label>Careggi University Hospital, Italy</aff>
<aff id="aff18-0961203312470729"><label>18</label>ADWP-EBMT Chair, Saint Louis Hospital, Unité de Médecine interne et Pathologie Vasculaire, Assistance Publique des Hôpitaux de Paris, Paris 7 University, INSERM 976 (Paris, FR), France</aff>
<author-notes>
<corresp id="corresp1-0961203312470729">David Jayne, Vasculitis and Lupus Service, Box 118, Dialysis Unit, Addenbrooke's Hospital, Hills Road, Cambridge, CB2 2QQ, United Kingdom. Email: <email>dj106@cam.ac.uk</email></corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>3</month>
<year>2013</year>
</pub-date>
<volume>22</volume>
<issue>3</issue>
<fpage>245</fpage>
<lpage>253</lpage>
<history>
<date date-type="received"><day>10</day><month>7</month><year>2012</year></date>
<date date-type="accepted"><day>13</day><month>11</month><year>2012</year></date>
</history>
<permissions>
<copyright-statement>© The Author(s) 2012. Reprints and permissions: sagepub.co.uk/journalsPermissions.nav</copyright-statement>
<copyright-year>2012</copyright-year>
<copyright-holder content-type="sage">SAGE Publications</copyright-holder>
</permissions>
<abstract>
<sec>
<title>Objectives</title>
<p>Patients with systemic lupus erythematosus (SLE) refractory to conventional immunosuppression suffer substantial morbidity and mortality due to active disease and treatment toxicity. Immunoablation followed by autologous stem cell transplantation (ASCT) is a novel therapeutic strategy that potentially offers new hope to these patients.</p>
</sec>
<sec>
<title>Methods</title>
<p>This retrospective survey reviews the efficacy and safety of ASCT in 28 SLE patients from eight centres reported to the European Group for Blood and Marrow Transplantation (EBMT) registry between 2001 and 2008.</p>
</sec>
<sec>
<title>Results</title>
<p>Median disease duration before ASCT was 52 (nine to 396) months, 25/28 SLE patients (89%) were female, age 29 (16–48) years. At the time of ASCT, eight (one to 11) American College of Rheumatology (ACR) diagnostic criteria for SLE were present and 17 (60%) patients had nephritis. Peripheral blood stem cells were mobilized with cyclophosphamide and granulocyte-colony stimulating factor in 93% of patients, and ex vivo CD34 stem cell selection was performed in 36%. Conditioning regimens were employed with either low (<italic>n</italic> = 10) or intermediate (18) intensities. With a median follow-up of 38 (one to 110) months after ASCT, the five-year overall survival was 81 ± 8%, disease-free survival was 29 ± 9%, relapse incidence (RI) was 56 ± 11% and non-relapse mortality was 15 ± 7%. Graft manipulation by CD34+ selection was associated with a lower RI (<italic>p</italic> = 0.001) on univariate analysis. There were five deaths within two years after ASCT: three caused by infection, one by secondary autoimmune disease and one by progressive SLE.</p>
</sec>
<sec>
<title>Conclusions</title>
<p>Our data further support the concept of immunoablation and ASCT to re-induce long-term clinical and serologic remissions in refractory SLE patients even in the absence of maintenance therapy. This study also suggests a beneficial effect of ex vivo graft manipulation on prevention of relapses post-transplantation in SLE.</p>
</sec>
</abstract>
<kwd-group>
<kwd>Systemic Lupus Erythematosus</kwd>
<kwd>Anti-DNA antibodies</kwd>
<kwd>Anticardiolipin Antibodies</kwd>
<kwd>Cardiovascular Disease</kwd>
<kwd>Haematologic changes</kwd>
<kwd>Nephritis</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="sec1-0961203312470729" sec-type="intro"><title>Introduction</title>
<p>Systemic lupus erythematosus (SLE) is a multisystem disease characterized by abnormal production of autoantibodies and tissue deposition of immune complexes leading to a diverse array of clinical manifestations.<sup><xref ref-type="bibr" rid="bibr1-0961203312470729">1</xref>,<xref ref-type="bibr" rid="bibr2-0961203312470729">2</xref></sup> Major organ manifestations, particularly central nervous system and renal disease, have long been identified as markers of poor prognosis.<sup><xref ref-type="bibr" rid="bibr3-0961203312470729">3</xref>,<xref ref-type="bibr" rid="bibr4-0961203312470729">4</xref></sup> SLE-related mortality has been reduced over the last few decades because of improved supportive care and more aggressive medical therapy, such as intravenous cyclophosphamide, mycophenolate mofetil and, more recently, immunotherapy.<sup><xref ref-type="bibr" rid="bibr5-0961203312470729">5</xref>,<xref ref-type="bibr" rid="bibr6-0961203312470729">6</xref></sup> Despite these advances, some patients continue to have significant morbidity and mortality from active disease and treatment toxicity.<sup><xref ref-type="bibr" rid="bibr7-0961203312470729">7</xref>–</sup><sup><xref ref-type="bibr" rid="bibr10-0961203312470729">10</xref></sup> There is a need for newer therapeutic approaches to improve long-term outcomes. Autologous haematopoietic stem cell transplantation (ASCT) has been used for refractory lupus patients with poor prognosis.<sup><xref ref-type="bibr" rid="bibr11-0961203312470729">11</xref>–</sup><sup><xref ref-type="bibr" rid="bibr16-0961203312470729">16</xref></sup> It aims to deplete autoreactive lymphocytes, especially those resistant to conventional therapy, and to replace the dysfunctional immune system with a healthy immune system newly arising from haematopoietic stem cells (“immune resetting”).<sup><xref ref-type="bibr" rid="bibr17-0961203312470729">17</xref>–</sup><sup><xref ref-type="bibr" rid="bibr21-0961203312470729">21</xref></sup> This should result, in turn, in longer remissions and lower cumulative drug exposure than conventional treatment.<sup><xref ref-type="bibr" rid="bibr22-0961203312470729">22</xref></sup></p>
<p>In a previous study, we published a retrospective analysis of the European Group for Blood and Marrow Transplantation and European League against Rheumatism (EBMT/EULAR) registry in 53 patients who received ASCT for SLE between 1996 and 2002.<sup><xref ref-type="bibr" rid="bibr13-0961203312470729">13</xref></sup> This study showed the efficacy of ASCT for remission induction of refractory SLE. However, ASCT was associated with a high transplant-related mortality of 12% at one year, and 32% subsequently relapsed.<sup><xref ref-type="bibr" rid="bibr13-0961203312470729">13</xref></sup> A comparable North American single-centre study of ASCT in SLE had lower treatment-related mortality of 2% (one of 50).<sup><xref ref-type="bibr" rid="bibr12-0961203312470729">12</xref></sup> This difference in treatment-related mortality between the American single-centre study and the European multicentre analysis was explained by a centre effect<sup><xref ref-type="bibr" rid="bibr16-0961203312470729">16</xref></sup> related to the conditioning regimen used, supportive care guidelines<sup><xref ref-type="bibr" rid="bibr23-0961203312470729">23</xref></sup> and experience in transplanting patients with SLE.<sup><xref ref-type="bibr" rid="bibr15-0961203312470729">15</xref>–</sup><sup><xref ref-type="bibr" rid="bibr23-0961203312470729">23</xref></sup> We are now analysing the outcome of new patients reported to the EBMT registry from 2001 to 2008.</p>
</sec>
<sec id="sec2-0961203312470729" sec-type="methods"><title>Methods</title>
<p>Ethical approval was obtained for this study from Cambridge University Hospital ethics committee. All EBMT centres were invited to participate in the study. For those centres that agreed to participate, primary data was collected, where available using a standardized pro forma, minimal essential data ‘B’ (MED-B) forms, SLE insert. This collected details of the transplant procedure, adverse events, American College of Rheumatology (ACR) diagnostic criteria, renal histology and previous therapy.<sup><xref ref-type="bibr" rid="bibr24-0961203312470729">24</xref></sup> There was sequential evaluation by SLE disease activity index (SLEDAI), serum creatinine, antinuclear antibodies (ANA), anti-double-stranded DNA antibodies (anti-dsDNA), anti-cardiolipin antibodies, other antinuclear autoantibodies and levels of the third and fourth complement components (C3, C4).<sup><xref ref-type="bibr" rid="bibr25-0961203312470729">25</xref></sup> Standard techniques for ASCT, as previously reported,<sup><xref ref-type="bibr" rid="bibr16-0961203312470729">16</xref>,<xref ref-type="bibr" rid="bibr22-0961203312470729">22</xref>,<xref ref-type="bibr" rid="bibr23-0961203312470729">23</xref></sup> were employed using peripheral blood stem cells as the source of stem cells and in most cases were mobilized with cyclophosphamide (2–4 g/m<sup>2</sup>) in combination with granulocyte-colony stimulating factor (G-CSF), or with G-CSF alone, according to local protocols. When performed, in vitro purging before ASCT used CD34<sup>+</sup>-positive selection according to local protocols. In order to analyse the effect of the various conditioning regimens on outcomes, the regimens were subgrouped, as previously used for analysis of outcome,<sup><xref ref-type="bibr" rid="bibr16-0961203312470729">16</xref></sup> into: (i) high-intensity regimens, including any busulfan- or total-body irradiation (TBI)-containing regimens; (ii) low-intensity regimens restricted to cyclophosphamide alone, melphalan alone and fludarabine-based regimens; and (iii) intermediate regimens, including all the other combinations. Evaluations were performed at mobilization, transplantation and last follow-up. Relapse was defined as an increase in SLEDAI by at least three or an increase in prednisolone to more than 10 mg/day or the introduction of an immunosuppressive drug after prior remission, according to physicians’ local protocols.</p>
<sec id="sec3-0961203312470729"><title>Statistical analysis</title>
<p>The probabilities of overall survival (OS), disease-free survival (DFS), relapse incidence (RI) and non-relapse mortality (NRM) were the primary study end-points. OS was defined as time to death, irrespective of the cause. The DFS was defined as the time interval from ASCT to either relapse or death, and was calculated using the Kaplan-Meier estimate. To evaluate RI, patients dying either from direct toxicity of the procedure or from any other cause not related to lupus were censored. The NRM was defined as death in the absence of relapse. The RI and NRM were calculated using cumulative incidence curves in a competing risks setting, death in remission being treated as a competing event to relapse.<sup><xref ref-type="bibr" rid="bibr26-0961203312470729">26</xref></sup> Univariate analyses were done with the use of log-rank test for OS and DFS while Gray’s test was applied for RI and NRM. Patient, disease and transplant-related variables were compared between patients receiving or not ex vivo CD34-selected cells, using the Fisher exact test for categorical and the Mann-Whitney test for continuous variables. All tests were two sided. The type I error rate was fixed at 0.05 for determination of factors associated with time to event outcomes. Statistical analyses were performed with SPSS 19 (Statistical Package for the Social Sciences Inc, Chicago) and R (R Development Core Team, Vienna, Austria) software packages. Repeated-measure analysis of variance (ANOVA) was used in order to compare SLEDAI values from mobilization to last follow-up. All tests were two sided. The type I error rate was fixed at 0.05 for determination of factors associated with time to event outcomes.</p>
</sec>
</sec>
<sec id="sec4-0961203312470729" sec-type="results"><title>Results</title>
<sec id="sec5-0961203312470729"><title>Population</title>
<p>Out of 48 consecutive first ASCT for SLE patients reported to the EBMT registry from 2001 to 2008, we were able to collect completed data for 28 SLE patients from eight centres in six countries. We first checked that the outcome was similar between the present study group of 28 patients and the 20 others reported to the EBMT registry during the time study period (two-year OS 81% vs 76%, respectively, <italic>p</italic> = 0.6, two-year DFS 55% vs 51%, <italic>p</italic> = 0.37). None of the 28 patients analysed in the present study were included in our previous report. Patient demographic details and clinical characteristics are shown in <xref ref-type="table" rid="table1-0961203312470729">Table 1</xref>. Seventeen had renal involvement at the time of mobilization: Of these, 10 had histological features of World Health Organization (WHO) Class II (four), III (two), IV (four) nephritis. The median (range) duration of follow-up after ASCT for surviving patients was 38 (one to 110) months.
<table-wrap id="table1-0961203312470729" position="float"><label>Table 1</label><caption><p>Clinical characteristics of the 28 SLE patients treated by autologous haematopoietic stem cell transplantation (ASCT) and reported to the EBMT registry between 2001 and 2008</p></caption>
<graphic alternate-form-of="table1-0961203312470729" xlink:href="10.1177_0961203312470729-table1.tif"/>
<table frame="hsides"><thead align="left">
<tr><th>Clinical characteristic</th>
<th>Number (percentage)</th>
</tr></thead>
<tbody align="left">
<tr>
<td>Sex (female)</td>
<td>25 (89%)</td>
</tr>
<tr>
<td>Age at transplant (median, years)</td>
<td>29 (16–48)</td>
</tr>
<tr>
<td>Disease duration prior to ASCT (median, months)</td>
<td>52 (9–396)</td>
</tr>
<tr>
<td>Follow-up (median, months)</td>
<td>38 (1–110)</td>
</tr>
<tr>
<td colspan="2"><bold>Lupus involvement at time of diagnosis</bold></td>
</tr>
<tr>
<td> Number of ACR criteria (median)</td>
<td>8 (1–11)</td>
</tr>
<tr>
<td> Renal disorder</td>
<td>21 (75%)</td>
</tr>
<tr>
<td> Neurologic disorder</td>
<td>12 (43%)</td>
</tr>
<tr>
<td> Haematological disorder</td>
<td>19 (68%)</td>
</tr>
<tr>
<td> Prior cyclophosphamide treatment</td>
<td>23 (82%)</td>
</tr>
<tr>
<td colspan="2"><bold>Lupus involvement prior to ASCT</bold></td>
</tr>
<tr>
<td>Positive anti-dsDNA</td>
<td>20/25 (80%)</td>
</tr>
<tr>
<td> Positive anti-cardiolipin (IgG/IgM)</td>
<td>9/20 (45%)</td>
</tr>
<tr>
<td>Nephritis (grade II/III/IV/missing)</td>
<td>17 (4/2/4/7) (60%)</td>
</tr>
<tr>
<td> SLEDAI &gt;20</td>
<td>7/28 (25%)</td>
</tr>
<tr>
<td> Serum creatinine &lt;150 µm/l</td>
<td>26/28 (93%)</td>
</tr>
<tr>
<td> 24-hour urinary protein &gt;3000 mg</td>
<td>2/26 (8%)</td>
</tr>
<tr>
<td> Complement component reduced (C3 or C4)</td>
<td>17/18 (94%)</td>
</tr>
<tr>
<td> Karnofsky performance score (≥80/&lt;80)</td>
<td>18/10 (64%/36%)</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-0961203312470729"><p>SLE: systemic lupus erythematosus; EBMT: European Group for Blood and Marrow Transplantation; ACR: American College of Rheumatology; anti-dsDNA: anti-double-stranded DNA; SLEDAI: Systemic Lupus Erythematosus Disease Activity Index.</p></fn></table-wrap-foot>
</table-wrap></p>
</sec>
<sec id="sec6-0961203312470729"><title>ASCT procedure</title>
<p>Stem cells were harvested from peripheral blood in all patients. All achieved prompt haematopoietic engraftment (absolute neutrophil count &gt;0.5 × 10<sup>9</sup>/l) with a median of 13 (seven to 20) days. The mobilization protocol comprised cyclophosphamide and G-CSF in 26/28 (93%) and G-CSF alone in two patients (<xref ref-type="table" rid="table2-0961203312470729">Table 2</xref>). Ex vivo purging before ASCT, using CD34<sup>+</sup>-positive selection, was performed in 10/28 (36%) while 18/28 (64%) had no graft manipulation. The median (range) dose of reinfused CD34+ stem cells was 4.2 (1.66–12) × 10<sup>6</sup> cells/kg. Conditioning regimens consisted of: low-intensity regimens with cyclophosphamide or melphalan alone in 10/28 (36%) or intermediate-intensity regimen with the combination of cyclophosphamide and anti-thymocyte globulin (ATG) with or without methylprednisolone (MP), or with fludarabine, thiotepa, alemtuzumab and melphalan in 18/28 (64%) (<xref ref-type="table" rid="table2-0961203312470729">Table 2</xref>).
<table-wrap id="table2-0961203312470729" position="float"><label>Table 2</label><caption><p>Autologous haematopoietic stem cell transplantation procedure for the 28 SLE patients reported to the EBMT registry between 2001 and 2008</p></caption>
<graphic alternate-form-of="table2-0961203312470729" xlink:href="10.1177_0961203312470729-table2.tif"/>
<table frame="hsides">
<tbody align="left">
<tr>
<td>Stem cell source</td>
<td/>
</tr>
<tr>
<td> Peripheral blood (PBSC)</td>
<td>28 (100%)</td>
</tr>
<tr>
<td colspan="2"><bold>Peripheral blood stem cell mobilization</bold></td>
</tr>
<tr>
<td> Cyclophosphamide + G-CSF</td>
<td>26 (93%)</td>
</tr>
<tr>
<td> G-CSF alone</td>
<td>2 (7%)</td>
</tr>
<tr>
<td colspan="2"><bold>Peripheral blood stem cell ex vivo manipulation</bold></td>
</tr>
<tr>
<td> None</td>
<td>18 (64%)</td>
</tr>
<tr>
<td> CD34<sup>+</sup> selection</td>
<td>10 (36%)</td>
</tr>
<tr>
<td colspan="2"><bold>Conditioning</bold></td>
</tr>
<tr>
<td> Low-intensity regimen</td>
<td>10 (36%)</td>
</tr>
<tr>
<td>  Cyclophosphamide</td>
<td>9 (32%)</td>
</tr>
<tr>
<td>  Melphalan</td>
<td>1 (4%)</td>
</tr>
<tr>
<td> Intermediate-intensity regimen</td>
<td>18 (64%)</td>
</tr>
<tr>
<td>  Cyclophosphamide + ATG</td>
<td>4 (14%)</td>
</tr>
<tr>
<td>  Cyclophosphamide + ATG + MP</td>
<td>7 (25%)</td>
</tr>
<tr>
<td>  Cyclophosphamide + ATG + fludarabine</td>
<td>3 (11%)</td>
</tr>
<tr>
<td>  Cyclophosphamide + ATG + thiotepa</td>
<td>1 (4%)</td>
</tr>
<tr>
<td>  Cyclophosphamide + thiotepa</td>
<td>2 (7%)</td>
</tr>
<tr>
<td>  Cyclophosphamide + fludarabine + MP + alemtuzumab</td>
<td>1 (4%)</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn2-0961203312470729"><p>SLE: systemic lupus erythematosus; EBMT: European Group for Blood and Marrow Transplantation; G-CSF granulocute-stimulating growth factor; ATG: anti-thymocyte globulin; MP: methylprednisolone.</p></fn></table-wrap-foot>
</table-wrap></p>
</sec>
<sec id="sec7-0961203312470729"><title>Outcome</title>
<p>In the whole cohort, the five-year OS was 81 ± 8% (<xref ref-type="fig" rid="fig1-0961203312470729">Figure 1</xref>), NRM was 15 ± 7%, RI was 56 ± 11% and DFS was 29 ± 9% (<xref ref-type="fig" rid="fig2-0961203312470729">Figure 2</xref>). Five deaths (17.9%) occurred within two years after ASCT: three due to infections (one, two and three months), one to secondary autoimmune haemolytic anaemia (15 months), and one was caused by SLE disease progression (24 months).
<fig id="fig1-0961203312470729" position="float"><label>Figure 1</label><caption><p>Overall survival (OS) after autologous haematopoietic stem cell transplantation (ASCT) procedure for the 28 SLE patients reported to the EBMT registry between 2001 and 2008.</p>
<p>SLE: systemic lupus erythematosus; EBMT: European Group for Blood and Marrow Transplantation.</p></caption><graphic xlink:href="10.1177_0961203312470729-fig1.tif"/>
</fig>
<fig id="fig2-0961203312470729" position="float"><label>Figure 2</label><caption><p>Disease-free survival (DFS) after autologous haematopoietic stem cell transplantation (ASCT) procedure for the 28 SLE patients reported to the EBMT registry between 2001 and 2008.</p>
<p>SLE: systemic lupus erythematosus; EBMT: European Group for Blood and Marrow Transplantation.</p></caption><graphic xlink:href="10.1177_0961203312470729-fig2.tif"/>
</fig></p>
<p>Results from univariate analysis for OS, DFS, RI and NRM are summarized in <xref ref-type="table" rid="table3-0961203312470729">Table 3</xref>. The three-year OS was 80 ± 11% in patients with a pre-ASCT disease course less than 52 months (median) versus 83 ± 11% in those with pre-ASCT disease course more than 52 months (<italic>p</italic> = 0.95). OS tended to be lower when using intermediate as compared to low-intensity conditioning (<italic>p</italic> = 0.08). OS was not significantly associated with the presence of renal, neurologic or haematologic involvement or of SLEDAI &gt;20 before ASCT, anti-DNA antibodies at mobilization or ex vivo graft manipulation.
<table-wrap id="table3-0961203312470729" position="float"><label>Table 3</label><caption><p>Univariate analysis of the various determinants for overall survival (OS), disease-free survival (DFS), relapse incidence (RI) and non-relapse mortality (NMR) among the 28 SLE patients treated by autologous haematopoietic stem cell transplantation and reported to the EBMT registry between 2001 and 2008</p></caption>
<graphic alternate-form-of="table3-0961203312470729" xlink:href="10.1177_0961203312470729-table3.tif"/>
<table frame="hsides"><thead align="left">
<tr><th/>
<th/>
<th>OS</th>
<th>DFS</th>
<th>RI</th>
<th>NRM</th>
</tr></thead>
<tbody align="left">
<tr>
<td rowspan="3">Age at transplant</td>
<td>&lt;Median</td>
<td>77 ± 11</td>
<td>40 ± 13</td>
<td>45 ± 14</td>
<td>15 ± 10</td>
</tr>
<tr>
<td>&gt;Median</td>
<td>85 ± 10</td>
<td>35 ± 14</td>
<td>50 ± 15</td>
<td>15 ± 10</td>
</tr>
<tr>
<td/>
<td>0.75</td>
<td>0.81</td>
<td>0.90</td>
<td>0.94</td>
</tr>
<tr>
<td rowspan="3">Interval from diagnosis to transplant transplant</td>
<td>&lt;Median</td>
<td>80 ± 10</td>
<td>39 ± 13</td>
<td>48 ± 14</td>
<td>13 ± 9</td>
</tr>
<tr>
<td>&gt;Median</td>
<td>83 ± 11</td>
<td>37 ± 14</td>
<td>46 ± 16</td>
<td>17 ± 11</td>
</tr>
<tr>
<td/>
<td>0.95</td>
<td>0.84</td>
<td>0.86</td>
<td>0.67</td>
</tr>
<tr>
<td rowspan="3">Renal disorder</td>
<td>Absent</td>
<td>100</td>
<td>29 ± 17</td>
<td>71 ± 20</td>
<td>0</td>
</tr>
<tr>
<td>Present</td>
<td>74 ± 10</td>
<td>42 ± 12</td>
<td>38 ± 12</td>
<td>20 ± 9</td>
</tr>
<tr>
<td/>
<td>0.17</td>
<td>0.72</td>
<td>0.14</td>
<td>0.21</td>
</tr>
<tr>
<td rowspan="3">Neurologic disorder</td>
<td>Absent</td>
<td>72 ± 12</td>
<td>39 ± 13</td>
<td>41 ± 13</td>
<td>20 ± 11</td>
</tr>
<tr>
<td>Present</td>
<td>92 ± 8</td>
<td>38 ± 15</td>
<td>54 ± 16</td>
<td>8 ± 8</td>
</tr>
<tr>
<td/>
<td>0.23</td>
<td>0.63</td>
<td>0.82</td>
<td>0.42</td>
</tr>
<tr>
<td rowspan="3">Haematologic disorder</td>
<td>Absent</td>
<td>100</td>
<td>38 ± 17</td>
<td>63 ± 19</td>
<td>0</td>
</tr>
<tr>
<td>Present</td>
<td>73 ± 11</td>
<td>38 ± 12</td>
<td>40 ± 12</td>
<td>21 ± 10</td>
</tr>
<tr>
<td/>
<td>0.12</td>
<td>0.92</td>
<td>0.17</td>
<td>0.16</td>
</tr>
<tr>
<td rowspan="3">Anti-dsDNA at mobilization</td>
<td>Negative</td>
<td>67 ± 27</td>
<td>67 ± 27</td>
<td>0</td>
<td>NA</td>
</tr>
<tr>
<td>Positive</td>
<td>80 ± 9</td>
<td>80 ± 9</td>
<td>30 ± 11</td>
<td>NA</td>
</tr>
<tr>
<td/>
<td>0.78</td>
<td>0.86</td>
<td>0.76</td>
<td/>
</tr>
<tr>
<td rowspan="3">Nephritis at mobilization or transplant</td>
<td>Absent</td>
<td>100</td>
<td>44 ± 17</td>
<td>56 ± 18</td>
<td>0</td>
</tr>
<tr>
<td>Present</td>
<td>71 ± 11</td>
<td>34 ± 12</td>
<td>43 ± 13</td>
<td>23 ± 10</td>
</tr>
<tr>
<td/>
<td>0.09</td>
<td>0.86</td>
<td>0.12</td>
<td>0.13</td>
</tr>
<tr>
<td rowspan="3">SLEDAI &gt;20 at mobilization or transplant</td>
<td>No</td>
<td>79 ± 9</td>
<td>33 ± 11</td>
<td>52 ± 12</td>
<td>15 ± 8</td>
</tr>
<tr>
<td>Yes</td>
<td>86 ± 13</td>
<td>54 ± 20</td>
<td>32 ± 21</td>
<td>14 ± 14</td>
</tr>
<tr>
<td/>
<td>0.78</td>
<td>0.46</td>
<td>0.46</td>
<td>0.99</td>
</tr>
<tr>
<td rowspan="3">Serum creatinine &lt;150 µm/l at mobilization or transplant</td>
<td>No</td>
<td>100</td>
<td>100.0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Yes</td>
<td>80 ± 8</td>
<td>34 ± 10</td>
<td>50 ± 11</td>
<td>16 ± 7</td>
</tr>
<tr>
<td/>
<td>0.56</td>
<td>0.19</td>
<td>0.25</td>
<td>0.58</td>
</tr>
<tr>
<td rowspan="3">Conditioning</td>
<td>Low</td>
<td>100</td>
<td>52 ± 17</td>
<td>48 ± 19</td>
<td>0</td>
</tr>
<tr>
<td>Intermediate</td>
<td>71 ± 11</td>
<td>31 ± 11</td>
<td>46 ± 13</td>
<td>23 ± 10</td>
</tr>
<tr>
<td/>
<td>0.08</td>
<td>0.4</td>
<td>0.61</td>
<td>0.13</td>
</tr>
<tr>
<td rowspan="3">Ex vivo manipulation of the cells</td>
<td>No</td>
<td>87 ± 8</td>
<td>26 ± 11</td>
<td>68 ± 13</td>
<td>6 ± 6</td>
</tr>
<tr>
<td>Yes</td>
<td>69 ± 15</td>
<td>57 ± 16</td>
<td>11 ± 11</td>
<td>31 ± 16</td>
</tr>
<tr>
<td/>
<td>0.21</td>
<td>0.054</td>
<td>0.0014</td>
<td>0.09</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn3-0961203312470729"><p>EBMT: European Group for Blood and Marrow Transplantation; Anti-dsDNA: anti-double-stranded DNA; SLEDAI: Systemic Lupus Erythematosus Disease Activity Index.</p></fn></table-wrap-foot>
</table-wrap></p>
<p>The three-year NRM was 0% in the low-intensity conditioning versus 23 ± 10% in the intermediate-intensity conditioning (<italic>p</italic> = 0.13.)</p>
<p>DFS and RI were not associated with any pre-ASCT variables (age at transplant, disease duration, presence of neurologic, haematologic or renal involvement or anti-dsDNA status before transplant), nor with the use of low versus intermediate regimens.</p>
<p>CD34<sup>+</sup> selection ex vivo graft manipulation was associated with a lower RI (11 ± 11 % vs 68 ± 13%, <italic>p</italic> = 0.001) and a trend to higher DFS (57 ± 16% vs 26 ± 11%, <italic>p</italic> = 0.054) at three years, as observed in patients receiving selected stem cells compared to those without (<xref ref-type="table" rid="table4-0961203312470729">Table 4</xref>).
<table-wrap id="table4-0961203312470729" position="float"><label>Table 4</label><caption><p>Baseline variables at time of transplant and the use of CD 34 selection</p></caption>
<graphic alternate-form-of="table4-0961203312470729" xlink:href="10.1177_0961203312470729-table4.tif"/>
<table frame="hsides"><thead align="left">
<tr><th colspan="2" rowspan="2"/><th colspan="2">Ex vivo manipulation of the cells<hr/></th>
<th rowspan="2"><italic>p</italic> value</th>
</tr>
<tr><th>No (<italic>n</italic> = 18)</th>
<th>Yes (<italic>n</italic> = 10)</th>
</tr></thead>
<tbody align="left">
<tr>
<td>Median age at transplant</td>
<td/>
<td>35 (18–48)</td>
<td>23 (16–42)</td>
<td>0.04</td>
</tr>
<tr>
<td>Interval from diagnosis to transplant</td>
<td/>
<td>45 (9–396)</td>
<td>66 (10–270)</td>
<td>0.72</td>
</tr>
<tr>
<td rowspan="2">Gender of the patient</td>
<td>Male</td>
<td>0 (0%)</td>
<td>3 (30%)</td>
<td/>
</tr>
<tr>
<td>Female</td>
<td>18 (100%)</td>
<td>7 (70%)</td>
<td>0.04</td>
</tr>
<tr>
<td rowspan="2">Renal disorder</td>
<td>Absent</td>
<td>6 (33%)</td>
<td>1 (10%)</td>
<td/>
</tr>
<tr>
<td>Present</td>
<td>12 (67%)</td>
<td>9 (90%)</td>
<td>0.36</td>
</tr>
<tr>
<td rowspan="2">Neurologic disorder</td>
<td>Absent</td>
<td>12 (67%)</td>
<td>4 (40%)</td>
<td/>
</tr>
<tr>
<td>Present</td>
<td>6 (33%)</td>
<td>6 (60%)</td>
<td>0.24</td>
</tr>
<tr>
<td rowspan="2">Haematologic disorder</td>
<td>Absent</td>
<td>8 (44%)</td>
<td>1 (10%)</td>
<td/>
</tr>
<tr>
<td>Present</td>
<td>10 (56%)</td>
<td>9 (90%)</td>
<td>0.1</td>
</tr>
<tr>
<td rowspan="2">Anti-dsDNA at mobilization</td>
<td>Negative</td>
<td>3 (20%)</td>
<td>2 (20%)</td>
<td/>
</tr>
<tr>
<td>Positive</td>
<td>12 (80%)</td>
<td>8 (80%)</td>
<td>1</td>
</tr>
<tr>
<td rowspan="2">SLEDAI &gt;20 at mobilization or transplant</td>
<td>No</td>
<td>15 (83%)</td>
<td>6 (60%)</td>
<td/>
</tr>
<tr>
<td>Yes</td>
<td>3 (17%)</td>
<td>4 (40%)</td>
<td>0.21</td>
</tr>
<tr>
<td rowspan="2">Nephritis at mobilization or transplant</td>
<td>No</td>
<td>9 (50%)</td>
<td>1 (10%)</td>
<td/>
</tr>
<tr>
<td>Yes</td>
<td>9 (50%)</td>
<td>9 (90%)</td>
<td>0.05</td>
</tr>
<tr>
<td rowspan="2">Serum creatinine &lt;150 µm/l at mobilization or transplant</td>
<td>No</td>
<td>0 (0%)</td>
<td>2 (20%)</td>
<td/>
</tr>
<tr>
<td>Yes</td>
<td>18 (100%)</td>
<td>8 (80%)</td>
<td>0.12</td>
</tr>
<tr>
<td rowspan="2">Complement component reduced (C3 or C4) at mobilization or transplant</td>
<td>No</td>
<td>1 (13%)</td>
<td>0 (0%)</td>
<td/>
</tr>
<tr>
<td>Yes</td>
<td>7 (88%)</td>
<td>10 (100%)</td>
<td>0.44</td>
</tr>
<tr>
<td rowspan="2">DNA/IgM/IgG</td>
<td>No</td>
<td>1 (7%)</td>
<td>1 (10%)</td>
<td/>
</tr>
<tr>
<td>Yes</td>
<td>13 (93%)</td>
<td>9 (90%)</td>
<td>1</td>
</tr>
<tr>
<td rowspan="2">Conditioning</td>
<td>Low</td>
<td>9 (50%)</td>
<td>1 (10%)</td>
<td/>
</tr>
<tr>
<td>Intermediate</td>
<td>9 (50%)</td>
<td>9 (90%)</td>
<td>0.05</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn4-0961203312470729"><p>Anti-dsDNA: anti-double-stranded DNA; SLEDAI: Systemic Lupus Erythematosus Disease Activity Index.</p></fn></table-wrap-foot>
</table-wrap></p>
<p>At last follow-up after ASCT, six of 28 (21%) patients had a SLEDAI below three, 13/23 (46%) patients had abnormal serological elevated anti-dsDNA, five of 10 (50%) had depressed complement levels and four of 12 (33%) had anticardiolipin antibodies. There was a significant decrease in SLEDAI from mobilization (mean: 15.5; 95% confidence interval (CI): 12–18.9) up to last follow-up (mean: 8.5; 95% CI: 5.3–11.3) <italic>p</italic> = 0.002 (<xref ref-type="fig" rid="fig3-0961203312470729">Figure 3</xref>).
<fig id="fig3-0961203312470729" position="float"><label>Figure 3</label><caption><p>Evolution of SLEDAI at mobilization, before autologous stem cell transplantation (ASCT) procedure and at last follow-up for 23 out of 28 SLE patients reported to the EBMT registry between 2001 and 2008 with a significant fall in SLEDAI at last follow-up after ASCT (<italic>p</italic> = 0.002).</p>
<p>SLEDAI: Systemic Lupus Erythematosus Disease Activity Index; FU: follow-up; EBMT: European Group for Blood and Marrow Transplantation.</p></caption><graphic xlink:href="10.1177_0961203312470729-fig3.tif"/>
</fig></p>
<p>No patient without pre-transplantation renal involvement developed post-transplantation nephritis or renal failure.</p>
</sec>
<sec id="sec8-0961203312470729"><title>Adverse events</title>
<p>Thirty-one severe or life-threatening adverse events were reported in 23 patients. Infections were the most common in 15. Severe immune events were reported in three. One developed post-transplant Epstein-Barr-associated lymphoproliferative disorder and was alive at six years’ follow-up. Two developed secondary autoimmune diseases: one with autoimmune haemolytic anaemia died from sepsis after a second autologous transplant and the other with acquired haemophilia was alive after five years. Two had cardiovascular events. No patient developed pathologic fracture.</p>
</sec>
<sec id="sec9-0961203312470729"><title>SLE therapy post-transplant</title>
<p>Of 20 patients, 12 (60%) had an immunosuppressive drug or biological agent introduced after ASCT. This was a planned intervention with either cyclosporine or mycophenolate in order to prevent relapse in three of 20 (25%), but all three relapsed. Prednisolone was withdrawn in four others of 26 (15%) and the 22/26 (85%) remaining patients were receiving prednisolone in doses of 3–100 mg daily at time of last follow-up.</p>
</sec>
</sec>
<sec id="sec10-0961203312470729" sec-type="discussion"><title>Discussion</title>
<p>In this retrospective study, we analysed the EBMT registry data on 28 patients who received ASCT for SLE between 2001 and 2008. Our data confirm the efficacy of ASCT for patients with refractory SLE, despite an increase in mortality as reported from the EBMT registry analysis of 53 previous patients.<sup><xref ref-type="bibr" rid="bibr13-0961203312470729">13</xref></sup> They also suggest a beneficial effect of ex vivo graft manipulation for prevention of relapses after ASCT for autoimmune diseases. The EBMT Autoimmune Diseases Working Party uses a large international network after 15 years of international collaboration, with free and voluntary data reporting in accordance with the EBMT rules (<ext-link ext-link-type="uri" xlink:href="www.ebmt.org">www.ebmt.org</ext-link>).<sup><xref ref-type="bibr" rid="bibr23-0961203312470729">23</xref></sup> These results reflect ongoing European experience, although all registry data analyses have limitations. Teams used different transplant techniques, but most of the EBMT-participating centres adhered to the broad indications and optimum treatment principles, which are regularly updated.<sup><xref ref-type="bibr" rid="bibr22-0961203312470729">22</xref>,<xref ref-type="bibr" rid="bibr23-0961203312470729">23</xref></sup> All EBMT-participating centres can be subjected to random EBMT audits to control the consistency of reported data. One drawback of the present study is that purging was related to centre strategy (with respectively four purging and four non-purging centres) and the relatively small number of patients studied (<italic>n</italic> = 28) prevent meaningful multivariate analysis.</p>
<p>The five-year OS after ASCT was 81%, despite a previous history of refractory or relapsing SLE indicating the potential efficacy of this procedure, as previously reported.<sup><xref ref-type="bibr" rid="bibr11-0961203312470729">11</xref>–</sup><sup><xref ref-type="bibr" rid="bibr16-0961203312470729">16</xref></sup> Although a relatively high relapse rate (56% at five years) was seen, these were generally mild in nature. The control of clinical lupus activity was reflected by the relative falls of anti-dsDNA, normalization of complement levels and the possibility to reduce or withdraw corticosteroids in some patients. Clinical improvement was reflected by a significant fall in SLEDAI in the 23 SLE patients for whom repeated evaluation was available before mobilization, at time of transplant and at last follow-up after ASCT (<xref ref-type="fig" rid="fig3-0961203312470729">Figure 3</xref>).</p>
<p>This is similar to our previous results among the first 53 SLE patients reported to the EBMT registry.<sup><xref ref-type="bibr" rid="bibr13-0961203312470729">13</xref></sup> As illustrated by patients’ demographics in the present cohort (<xref ref-type="table" rid="table1-0961203312470729">Table 1</xref>), all were refractory to first- or second-line standard therapy.</p>
<p>SLEDAI has been shown to have a high prognostic value for death in conventionally treated SLE patients.<sup><xref ref-type="bibr" rid="bibr6-0961203312470729">6</xref>–</sup><sup><xref ref-type="bibr" rid="bibr10-0961203312470729">10</xref>,<xref ref-type="bibr" rid="bibr27-0961203312470729">27</xref>–</sup><sup><xref ref-type="bibr" rid="bibr30-0961203312470729">30</xref></sup> In the previous EBMT report, the mortality risk increased by five- and 14-fold for those with SLEDAI of greater than 10 and 20, respectively.<sup><xref ref-type="bibr" rid="bibr13-0961203312470729">13</xref></sup> In the present study, no correlation between baseline SLEDAI and NRM was found, suggesting that survival following ASCT may be related to other factors, including patient selection and centre experience,<sup><xref ref-type="bibr" rid="bibr16-0961203312470729">16</xref></sup> that influence transplant-related mortality and overall survival.</p>
<p>Transplant-related mortality is one of the major limitations of ASCT in SLE patients. While analysing the EBMT registry data among 900 first ASCT for various types of severe autoimmune diseases,<sup><xref ref-type="bibr" rid="bibr16-0961203312470729">16</xref></sup> patients with SLE had the highest 100-day transplant-related mortality (11%) and highest five-year post-transplant mortality (24%) of all autoimmune diseases. The overall survival of 81% in our cohort of transplanted SLE patients should be weighed against the 69% survival at five years for severe SLE with a poor treatment response, and the increased risk of death in SLE with increasing disease activity in conventionally treated SLE patients.<sup><xref ref-type="bibr" rid="bibr27-0961203312470729">27</xref>–</sup><sup><xref ref-type="bibr" rid="bibr30-0961203312470729">30</xref></sup> Over the years it has become evident that patient selection and timing of ASCT is highly relevant for the treatment outcome. Whenever possible, ASCT should be considered as a disease-modifying intervention to be utilized in the early stages of patently aggressive disease rather than a last resource salvage therapy in the face of vital organ dysfunction.<sup><xref ref-type="bibr" rid="bibr22-0961203312470729">22</xref>,<xref ref-type="bibr" rid="bibr23-0961203312470729">23</xref></sup></p>
<p>The relapse incidence was 56% at five years, which is comparable to data provided by the single-centre experience on ASCT for SLE from Chicago, suggesting that ASCT is effective in inducing useful periods of disease remission.<sup><xref ref-type="bibr" rid="bibr12-0961203312470729">12</xref></sup> Relapse may result from persistence of plasma cells despite conditioning with insufficient ablation of immunologic memory and sustained autoreactive antibodies.<sup><xref ref-type="bibr" rid="bibr19-0961203312470729">19</xref>–</sup><sup><xref ref-type="bibr" rid="bibr21-0961203312470729">21</xref></sup> In addition, ASCT does not correct underlying genetic susceptibility, and the disease may restart in the regenerated immune system.<sup><xref ref-type="bibr" rid="bibr31-0961203312470729">31</xref></sup> Importantly, relapse may result from reinfusion of autoreactive T-lymphocytes at the time of stem cell rescue.</p>
<p>In this cohort, the five-year DFS of 29% is lower compared to previous results already published.<sup><xref ref-type="bibr" rid="bibr16-0961203312470729">16</xref></sup> This can be explained by a longer follow-up without any plateau on the relapse curve.</p>
<p>The present study enabled us to suggest that ex vivo graft manipulation by positive selection of CD34 was associated with improved DFS and decreased RI. However, the small number of patients does not allow for the adjustment for factors differing between the two groups (<xref ref-type="table" rid="table4-0961203312470729">Table 4</xref>). The rationale of CD34<sup>+</sup> selection is to prevent reinfusion of disease-causing lymphocytes and thereby relapse. So far, there has been no data to support graft manipulation strategies as a means of improving outcome. The only study evaluating infusion of a CD34<sup>+</sup>-selected versus an unmanipulated graft compared two cohorts of patients with rheumatoid arthritis undergoing ASCT in Australia.<sup><xref ref-type="bibr" rid="bibr32-0961203312470729">32</xref></sup> The group receiving unselected stem cells (i.e. contaminated with lymphocytes) had a trend toward longer duration of clinical improvement.<sup><xref ref-type="bibr" rid="bibr32-0961203312470729">32</xref></sup> One potential explanation was that CD34<sup>+</sup> selection also removed disease-controlling regulatory T cells.<sup><xref ref-type="bibr" rid="bibr19-0961203312470729">19</xref></sup> Thus, the value of graft manipulation still warrants further investigation and larger clinical trials.</p>
<p>Bone marrow stem cells are reduced in SLE and have a high rate of apoptosis.<sup><xref ref-type="bibr" rid="bibr33-0961203312470729">33</xref>–</sup><sup><xref ref-type="bibr" rid="bibr35-0961203312470729">35</xref></sup> Nonetheless, stem cell mobilization and harvesting, typically with cyclophosphamide and G-CSF, was successful. However, combining CD34<sup>+</sup> selection with intensive immunosuppressive (myeloablative or lymphoablative) regimens or a long-acting lymphocyte-specific agent, such as alemtuzumab (anti-CD52 antibody against T and B cells and macrophages), as an alternative to ATG are likely to increase the risk of post-transplant opportunistic infections<sup><xref ref-type="bibr" rid="bibr20-0961203312470729">20</xref></sup> and of a secondary autoimmune disorder.<sup><xref ref-type="bibr" rid="bibr36-0961203312470729">36</xref></sup></p>
<p>The increasing utilization of B cell targeted biological agents, such as belimumab and rituximab, may account for the limited transplant activity in SLE,<sup><xref ref-type="bibr" rid="bibr15-0961203312470729">15</xref></sup> although only belimumab has proven efficacy in phase III randomized trials.<sup><xref ref-type="bibr" rid="bibr37-0961203312470729">37</xref></sup> In spite of the inherent difficulties, only prospective international studies are capable of delivering robust evidence on the efficacy and safety of ASCT with CD34<sup>+</sup> selection compared with current comparator treatments and whether post-transplant maintenance therapy improves long-term outcomes.</p>
</sec>
</body>
<back><ack>
<title>Acknowledgement</title>
<p>D Jayne is supported by the Cambridge Biomedical Research Centre.</p>
</ack>
<sec id="sec15-0961203312470729">
<title>Funding</title>
<p>This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.</p>
</sec>
<sec id="sec16-0961203312470729">
<title>Conflict of interest statement</title>
<p>The authors have no conflicts of interest to declare.</p>
</sec>
<ref-list>
<title>References</title>
<ref id="bibr1-0961203312470729"><label>1</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lipsky</surname><given-names>PE</given-names></name></person-group>. <article-title>Systemic lupus erythematosus: An autoimmune disease of B cell hyperactivity</article-title>. <source>Nat Immunol</source> <year>2001</year>; <volume>2</volume>: <fpage>764</fpage>–<lpage>766</lpage>.</citation></ref>
<ref id="bibr2-0961203312470729"><label>2</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rahman</surname><given-names>A</given-names></name><name><surname>Isenberg</surname><given-names>DA</given-names></name></person-group>. <article-title>Systemic lupus erythematosus</article-title>. <source>N Engl J Med</source> <year>2008</year>; <volume>358</volume>: <fpage>929</fpage>–<lpage>939</lpage>.</citation></ref>
<ref id="bibr3-0961203312470729"><label>3</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tokano</surname><given-names>Y</given-names></name><name><surname>Morimoto</surname><given-names>S</given-names></name><name><surname>Amano</surname><given-names>H</given-names></name><etal/></person-group>. <article-title>The relationship between initial clinical manifestation and long-term prognosis of patients with systemic lupus erythematosus</article-title>. <source>Mod Rheumatol</source> <year>2005</year>; <volume>15</volume>: <fpage>275</fpage>–<lpage>282</lpage>.</citation></ref>
<ref id="bibr4-0961203312470729"><label>4</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cervera</surname><given-names>R</given-names></name><name><surname>Khamashta</surname><given-names>MA</given-names></name><name><surname>Font</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>Morbidity and mortality in systemic lupus erythematosus during a 5-year period. A multicenter prospective study of 1,000 patients. European Working Party on Systemic Lupus Erythematosus</article-title>. <source>Medicine (Baltimore)</source> <year>1999</year>; <volume>78</volume>: <fpage>167</fpage>–<lpage>175</lpage>.</citation></ref>
<ref id="bibr5-0961203312470729"><label>5</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fiehn</surname><given-names>C</given-names></name><name><surname>Hajjar</surname><given-names>Y</given-names></name><name><surname>Mueller</surname><given-names>K</given-names></name><name><surname>Waldherr</surname><given-names>R</given-names></name><name><surname>Ho</surname><given-names>AD</given-names></name><name><surname>Andrassy</surname><given-names>K</given-names></name></person-group>. <article-title>Improved clinical outcome of lupus nephritis during the past decade: Importance of early diagnosis and treatment</article-title>. <source>Ann Rheum Dis</source> <year>2003</year>; <volume>62</volume>: <fpage>435</fpage>–<lpage>539</lpage>.</citation></ref>
<ref id="bibr6-0961203312470729"><label>6</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Diaz-Lagares</surname><given-names>C</given-names></name><name><surname>Croca</surname><given-names>S</given-names></name><name><surname>Sangle</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>Efficacy of rituximab in 164 patients with biopsy-proven lupus nephritis: Pooled data from European cohorts</article-title>. <source>Autoimmun Rev</source> <year>2012</year>; <volume>3</volume>: <fpage>357</fpage>–<lpage>364</lpage>.</citation></ref>
<ref id="bibr7-0961203312470729"><label>7</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ippolito</surname><given-names>A</given-names></name><name><surname>Petri</surname><given-names>M</given-names></name></person-group>. <article-title>An update on mortality in systemic lupus erythematosus</article-title>. <source>Clin Exp Rheumatol</source> <year>2008</year>; <volume>26</volume>: <fpage>S72</fpage>–<lpage>S79</lpage>.</citation></ref>
<ref id="bibr8-0961203312470729"><label>8</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bernatsky</surname><given-names>S</given-names></name><name><surname>Boivin</surname><given-names>JF</given-names></name><name><surname>Joseph</surname><given-names>L</given-names></name><etal/></person-group>. <article-title>Mortality in systemic lupus erythematosus</article-title>. <source>Arthritis Rheum</source> <year>2006</year>; <volume>54</volume>: <fpage>2550</fpage>–<lpage>2557</lpage>.</citation></ref>
<ref id="bibr9-0961203312470729"><label>9</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Moss</surname><given-names>KE</given-names></name><name><surname>Ioannou</surname><given-names>Y</given-names></name><name><surname>Sultan</surname><given-names>SM</given-names></name><name><surname>Haq</surname><given-names>I</given-names></name><name><surname>Isenberg</surname><given-names>DA</given-names></name></person-group>. <article-title>Outcome of a cohort of 300 patients with systemic lupus erythematosus attending a dedicated clinic for over two decades</article-title>. <source>Ann Rheum Dis</source> <year>2002</year>; <volume>61</volume>: <fpage>409</fpage>–<lpage>413</lpage>.</citation></ref>
<ref id="bibr10-0961203312470729"><label>10</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Doria</surname><given-names>A</given-names></name><name><surname>Iaccarino</surname><given-names>L</given-names></name><name><surname>Ghirardello</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>Long-term prognosis and causes of death in systemic lupus erythematosus</article-title>. <source>Am J Med</source> <year>2006</year>; <volume>119</volume>: <fpage>700</fpage>–<lpage>706</lpage>.</citation></ref>
<ref id="bibr11-0961203312470729"><label>11</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Traynor</surname><given-names>AE</given-names></name><name><surname>Schroeder</surname><given-names>J</given-names></name><name><surname>Rosa</surname><given-names>RM</given-names></name><etal/></person-group>. <article-title>Treatment of severe systemic lupus erythematosus with high-dose chemotherapy and haemopoietic stem-cell transplantation: A phase I study</article-title>. <source>Lancet</source> <year>2000</year>; <volume>356</volume>: <fpage>701</fpage>–<lpage>707</lpage>.</citation></ref>
<ref id="bibr12-0961203312470729"><label>12</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Burt</surname><given-names>RK</given-names></name><name><surname>Traynor</surname><given-names>A</given-names></name><name><surname>Statkute</surname><given-names>L</given-names></name><etal/></person-group>. <article-title>Nonmyeloablative hematopoietic stem cell transplantation for systemic lupus erythematosus</article-title>. <source>JAMA</source> <year>2006</year>; <volume>295</volume>: <fpage>527</fpage>–<lpage>535</lpage>.</citation></ref>
<ref id="bibr13-0961203312470729"><label>13</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jayne</surname><given-names>D</given-names></name><name><surname>Passweg</surname><given-names>J</given-names></name><name><surname>Marmont</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>European Group for Blood and Marrow Transplantation; European League Against Rheumatism Registry. Autologous stem cell transplantation for systemic lupus erythematosus</article-title>. <source>Lupus</source> <year>2004</year>; <volume>13</volume>: <fpage>168</fpage>–<lpage>176</lpage>.</citation></ref>
<ref id="bibr14-0961203312470729"><label>14</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>L</given-names></name></person-group>. <article-title>Stem cell transplantation: Progress in Asia</article-title>. <source>Lupus</source> <year>2010</year>; <volume>19</volume>: <fpage>1468</fpage>–<lpage>1473</lpage>.</citation></ref>
<ref id="bibr15-0961203312470729"><label>15</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Petri</surname><given-names>M</given-names></name><name><surname>Brodsky</surname><given-names>R</given-names></name></person-group>. <article-title>High-dose cyclophosphamide and stem cell transplantation for refractory systemic lupus erythematosus</article-title>. <source>JAMA</source> <year>2006</year>; <volume>295</volume>: <fpage>559</fpage>–<lpage>560</lpage>.</citation></ref>
<ref id="bibr16-0961203312470729"><label>16</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Farge</surname><given-names>D</given-names></name><name><surname>Labopin</surname><given-names>M</given-names></name><name><surname>Tyndall</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>Autologous hematopoietic stem cell transplantation for autoimmune diseases: An observational study on 12 years' experience from the European Group for Blood and Marrow Transplantation Working Party on Autoimmune Diseases</article-title>. <source>Haematologica</source> <year>2010</year>; <volume>95</volume>: <fpage>284</fpage>–<lpage>292</lpage>.</citation></ref>
<ref id="bibr17-0961203312470729"><label>17</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ikehara</surname><given-names>S</given-names></name><name><surname>Good</surname><given-names>RA</given-names></name><name><surname>Nakamura</surname><given-names>T</given-names></name><etal/></person-group>. <article-title>Rationale for bone marrow transplantation in the treatment of autoimmune diseases</article-title>. <source>Proc Natl Acad Sci U S A</source> <year>1985</year>; <volume>82</volume>: <fpage>2483</fpage>–<lpage>2487</lpage>.</citation></ref>
<ref id="bibr18-0961203312470729"><label>18</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Muraro</surname><given-names>PA</given-names></name><name><surname>Douek</surname><given-names>DC</given-names></name></person-group>. <article-title>Renewing the T cell repertoire to arrest autoimmune aggression</article-title>. <source>Trends Immunol</source> <year>2006</year>; <volume>27</volume>: <fpage>61</fpage>–<lpage>67</lpage>.</citation></ref>
<ref id="bibr19-0961203312470729"><label>19</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Bertucci</surname><given-names>AM</given-names></name><name><surname>Ramsey-Goldman</surname><given-names>R</given-names></name><etal/></person-group>. <article-title>Regulatory T cell (Treg) subsets return in patients with refractory lupus following stem cell transplantation, and TGF-beta-producing CD8+ Treg cells are associated with immunological remission of lupus</article-title>. <source>J Immunol</source> <year>2009</year>; <volume>183</volume>: <fpage>6346</fpage>–<lpage>6358</lpage>.</citation></ref>
<ref id="bibr20-0961203312470729"><label>20</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Burt</surname><given-names>RK</given-names></name><name><surname>Slavin</surname><given-names>S</given-names></name><name><surname>Burns</surname><given-names>WH</given-names></name><name><surname>Marmont</surname><given-names>AM</given-names></name></person-group>. <article-title>Induction of tolerance in autoimmune diseases by hematopoietic stem cell transplantation: Getting closer to a cure?</article-title> <source>Blood</source> <year>2002</year>; <volume>99</volume>: <fpage>768</fpage>–<lpage>784</lpage>.</citation></ref>
<ref id="bibr21-0961203312470729"><label>21</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Alexander</surname><given-names>T</given-names></name><name><surname>Thiel</surname><given-names>A</given-names></name><name><surname>Rosen</surname><given-names>O</given-names></name><etal/></person-group>. <article-title>Depletion of autoreactive immunologic memory followed by autologous hematopoietic stem cell transplantation in patients with refractory SLE induces long-term remission through de novo generation of a juvenile and tolerant immune system</article-title>. <source>Blood</source> <year>2009</year>; <volume>113</volume>: <fpage>214</fpage>–<lpage>223</lpage>.</citation></ref>
<ref id="bibr22-0961203312470729"><label>22</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Illei</surname><given-names>GG</given-names></name><name><surname>Cervera</surname><given-names>R</given-names></name><name><surname>Burt</surname><given-names>RK</given-names></name><etal/></person-group>. <article-title>Current state and future directions of autologous hematopoietic stem cell transplantation in systemic lupus erythematosus</article-title>. <source>Ann Rheum Dis</source> <year>2011</year>; <volume>70</volume>: <fpage>2071</fpage>–<lpage>2074</lpage>.</citation></ref>
<ref id="bibr23-0961203312470729"><label>23</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Snowden</surname><given-names>JA</given-names></name><name><surname>Saccardi</surname><given-names>R</given-names></name><name><surname>Allez</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Haematopoietic SCT in severe autoimmune diseases: Updated guidelines of the European Group for Blood and Marrow Transplantation</article-title>. <source>Bone Marrow Transplant</source> <year>2012</year>; <volume>46</volume>: <fpage>77</fpage>–<lpage>90</lpage>.</citation></ref>
<ref id="bibr24-0961203312470729"><label>24</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hochberg</surname><given-names>MC</given-names></name></person-group>. <article-title>Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus</article-title>. <source>Arthritis Rheum</source> <year>1997</year>; <volume>40</volume>: <fpage>1725</fpage>–<lpage>1725</lpage>.</citation></ref>
<ref id="bibr25-0961203312470729"><label>25</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yee</surname><given-names>CS</given-names></name><name><surname>Farewell</surname><given-names>VT</given-names></name><name><surname>Isenberg</surname><given-names>DA</given-names></name><etal/></person-group>. <article-title>The use of Systemic Lupus Erythematosus Disease Activity Index-2000 to define active disease and minimal clinically meaningful change based on data from a large cohort of systemic lupus erythematosus patients</article-title>. <source>Rheumatology (Oxford)</source> <year>2011</year>; <volume>50</volume>: <fpage>982</fpage>–<lpage>988</lpage>.</citation></ref>
<ref id="bibr26-0961203312470729"><label>26</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gooley</surname><given-names>TA</given-names></name><name><surname>Leisenring</surname><given-names>W</given-names></name><name><surname>Crowley</surname><given-names>J</given-names></name><name><surname>Storer</surname><given-names>BE</given-names></name></person-group>. <article-title>Estimation of failure probabilities in the presence of competing risks: New representations of old estimators</article-title>. <source>Stat Med</source> <year>1999</year>; <volume>18</volume>: <fpage>695</fpage>–<lpage>706</lpage>.</citation></ref>
<ref id="bibr27-0961203312470729"><label>27</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cook</surname><given-names>RJ</given-names></name><name><surname>Gladman</surname><given-names>DD</given-names></name><name><surname>Pericak</surname><given-names>D</given-names></name><name><surname>Urowitz</surname><given-names>MB</given-names></name></person-group>. <article-title>Prediction of short term mortality in systemic lupus erythematosus with time dependent measures of disease activity</article-title>. <source>J Rheumatol</source> <year>2000</year>; <volume>27</volume>: <fpage>1892</fpage>–<lpage>1895</lpage>.</citation></ref>
<ref id="bibr28-0961203312470729"><label>28</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zonana-Nacach</surname><given-names>A</given-names></name><name><surname>Yañez</surname><given-names>P</given-names></name><name><surname>Jiménez-Balderas</surname><given-names>FJ</given-names></name><name><surname>Camargo-Coronel</surname><given-names>A</given-names></name></person-group>. <article-title>Disease activity, damage and survival in Mexican patients with acute severe systemic lupus erythematosus</article-title>. <source>Lupus</source> <year>2007</year>; <volume>16</volume>: <fpage>997</fpage>–<lpage>1000</lpage>.</citation></ref>
<ref id="bibr29-0961203312470729"><label>29</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nossent</surname><given-names>J</given-names></name><name><surname>Cikes</surname><given-names>N</given-names></name><name><surname>Kiss</surname><given-names>E</given-names></name><etal/></person-group>. <article-title>Current causes of death in systemic lupus erythematosus in Europe, 2000–2004: Relation to disease activity and damage accrual</article-title>. <source>Lupus</source> <year>2007</year>; <volume>16</volume>: <fpage>309</fpage>–<lpage>317</lpage>.</citation></ref>
<ref id="bibr30-0961203312470729"><label>30</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>To</surname><given-names>CH</given-names></name><name><surname>Mok</surname><given-names>CC</given-names></name><name><surname>Tang</surname><given-names>SS</given-names></name><name><surname>Ying</surname><given-names>SK</given-names></name><name><surname>Wong</surname><given-names>RW</given-names></name><name><surname>Lau</surname><given-names>CS</given-names></name></person-group>. <article-title>Prognostically distinct clinical patterns of systemic lupus erythematosus identified by cluster analysis</article-title>. <source>Lupus</source> <year>2009</year>; <volume>18</volume>: <fpage>1267</fpage>–<lpage>1275</lpage>.</citation></ref>
<ref id="bibr31-0961203312470729"><label>31</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rosen</surname><given-names>O</given-names></name><name><surname>Hiepe</surname><given-names>F</given-names></name><name><surname>Massenkeil</surname><given-names>G</given-names></name><name><surname>Thiel</surname><given-names>A</given-names></name><name><surname>Arnold</surname><given-names>R</given-names></name></person-group>. <article-title>Relapse of systemic lupus erythematosus</article-title>. <source>Lancet</source> <year>2001</year>; <volume>357</volume>: <fpage>807</fpage>–<lpage>808</lpage>.</citation></ref>
<ref id="bibr32-0961203312470729"><label>32</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Moore</surname><given-names>J</given-names></name><name><surname>Brooks</surname><given-names>P</given-names></name><name><surname>Milliken</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>A pilot randomized trial comparing CD34-selected versus unmanipulated hemopoietic stem cell transplantation for severe, refractory rheumatoid arthritis</article-title>. <source>Arthritis Rheum</source> <year>2002</year>; <volume>46</volume>: <fpage>2301</fpage>–<lpage>2309</lpage>.</citation></ref>
<ref id="bibr33-0961203312470729"><label>33</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ramos</surname><given-names>PS</given-names></name><name><surname>Brown</surname><given-names>EE</given-names></name><name><surname>Kimberly</surname><given-names>RP</given-names></name><name><surname>Langefeld</surname><given-names>CD</given-names></name></person-group>. <article-title>Genetic factors predisposing to systemic lupus erythematosus and lupus nephritis</article-title>. <source>Semin Nephrol</source> <year>2010</year>; <volume>30</volume>: <fpage>164</fpage>–<lpage>176</lpage>.</citation></ref>
<ref id="bibr34-0961203312470729"><label>34</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Papadaki</surname><given-names>HA</given-names></name><name><surname>Boumpas</surname><given-names>DT</given-names></name><name><surname>Gibson</surname><given-names>FM</given-names></name><etal/></person-group>. <article-title>Increased apoptosis of bone marrow CD34(+) cells and impaired function of bone marrow stromal cells in patients with systemic lupus erythematosus</article-title>. <source>Br J Haematol</source> <year>2001</year>; <volume>115</volume>: <fpage>167</fpage>–<lpage>174</lpage>.</citation></ref>
<ref id="bibr35-0961203312470729"><label>35</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pyrovolaki</surname><given-names>K</given-names></name><name><surname>Mavroudi</surname><given-names>I</given-names></name><name><surname>Sidiropoulos</surname><given-names>P</given-names></name><name><surname>Eliopoulos</surname><given-names>AG</given-names></name><name><surname>Boumpas</surname><given-names>DT</given-names></name><name><surname>Papadaki</surname><given-names>HA</given-names></name></person-group>. <article-title>Increased expression of CD40 on bone marrow CD34+ hematopoietic progenitor cells in patients with systemic lupus erythematosus: Contribution to Fas-mediated apoptosis</article-title>. <source>Arthritis Rheum</source> <year>2009</year>; <volume>60</volume>: <fpage>543</fpage>–<lpage>552</lpage>.</citation></ref>
<ref id="bibr36-0961203312470729"><label>36</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Daikeler</surname><given-names>T</given-names></name><name><surname>Labopin</surname><given-names>M</given-names></name><name><surname>Di Gioia</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>EBMT Autoimmune Disease Working Party. Secondary autoimmune diseases occurring after HSCT for an autoimmune disease: A retrospective study of the EBMT Autoimmune Disease Working Party</article-title>. <source>Blood</source> <year>2011</year>; <volume>118</volume>: <fpage>1693</fpage>–<lpage>1698</lpage>.</citation></ref>
<ref id="bibr37-0961203312470729"><label>37</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Catapano</surname><given-names>F</given-names></name><name><surname>Chaudhry</surname><given-names>AN</given-names></name><name><surname>Jones</surname><given-names>RB</given-names></name><name><surname>Smith</surname><given-names>KG</given-names></name><name><surname>Jayne</surname><given-names>DW</given-names></name></person-group>. <article-title>Long-term efficacy and safety of rituximab in refractory and relapsing systemic lupus erythematosus</article-title>. <source>Nephrol Dial Transplant</source> <year>2010</year>; <volume>25</volume>: <fpage>3586</fpage>–<lpage>3592</lpage>.</citation></ref>
</ref-list>
</back>
</article>